Biotech IN8bio Boosts Preclinical Spending on Cancer Platform
The quarterly figures show research costs rising as the company prepares initial preclinical data for INB-619 by year-end 2026.
Updated on Nov. 5, 2026 in Biotech

IN8bio reported a net loss of $4.6 million, or $0.24 per share, for the quarter ended September 30, 2026, compared with $3.9 million, or $0.85 per share, a year earlier. The results are from a clinical-stage company; its INB-619 program is at the preclinical stage, not approved or in human trials.
Why it matters
Higher research spending on the company's T cell engager platform shows preclinical work is consuming more capital while cash rose to $14.0 million from $10.7 million a year earlier. The results signal how early-stage cell therapy developers are funding discovery work before any clinical readouts.
The figures come from IN8bio's quarterly financial results, comparing the three months ended September 30, 2026 with the same period in 2025. Net loss rose to $4.6 million from $3.9 million, driven by R&D expenses of $2.6 million against $2.1 million, while the company's reported cash balance reached $14.0 million. Whether the company will need additional capital before its next milestone is not addressed in the source.
The players
IN8bio
A clinical-stage biotechnology company developing gamma delta T cell therapies and a T cell engager platform for cancer treatment.
Oxana Polyakova, Ph.D.
A scientist who joined IN8bio in September 2026 as Senior Vice President of Research & Development.
The details
IN8bio's R&D costs increased primarily because of preclinical work on its T cell engager platform, a class of drug designed to link immune T cells to cancer cells. The company says it remains on track to report initial in vivo preclinical data for INB-619, its lead program in that platform, by year-end 2026. In vivo means the data come from studies in living animals, which is an early step before any human testing.
Timeline
July 2026: IN8bio published Phase 1 INB-200 glioblastoma data in the Journal of Clinical Oncology.
September 2026: Oxana Polyakova, Ph.D., joined the company as Senior Vice President of Research & Development.
October 2026: INB-619 was included in a review published in Nature Reviews Drug Discovery.
September 30, 2026: The quarter ended, with the net loss and cash position reported.
Year-end 2026: The company expects initial in vivo preclinical data for INB-619.
The Tech Race
IN8bio's INB-619 program is at the preclinical stage, meaning its data comes from animal studies rather than human trials. The company's spending on this platform reflects how cancer biotechnology developers are moving from earlier cell therapy work toward T cell engagers.
For patients, this quarter's results do not change access to any treatment, since INB-619 is preclinical and has no approved use. The next concrete signal is the preclinical data expected by year-end 2026, which would indicate whether the program advances toward human testing.
The takeaway
Watch for the year-end 2026 in vivo preclinical data for INB-619, the first concrete test of the T cell engager platform. A positive readout would be a step toward human trials, while the company's ongoing R&D spending suggests the program will continue to need capital before it reaches the clinic.
What happens next
The company expects to report initial in vivo preclinical data for INB-619 by year-end 2026.
Further reading
For broader context on drug development pipelines, explore Biotech coverage.
Source note: This article includes information reported by The Manila times.





